中国卫生标准管理2024,Vol.15Issue(20) :143-146.DOI:10.3969/j.issn.1674-9316.2024.20.033

常规治疗联合曲美他嗪治疗心肌缺血再灌注损伤的作用

Effect of Conventional Therapy Combined With Trimetazidine Treatment on Myocardial Ischemia-Reperfusion Injury

陈智浩 黄志航 蒋金鑫 苏灿锋 周飞
中国卫生标准管理2024,Vol.15Issue(20) :143-146.DOI:10.3969/j.issn.1674-9316.2024.20.033

常规治疗联合曲美他嗪治疗心肌缺血再灌注损伤的作用

Effect of Conventional Therapy Combined With Trimetazidine Treatment on Myocardial Ischemia-Reperfusion Injury

陈智浩 1黄志航 1蒋金鑫 1苏灿锋 1周飞2
扫码查看

作者信息

  • 1. 厦门大学附属翔安医院心血管内科,福建 厦门 361001
  • 2. 宜昌市中心人民医院心血管内科,湖北宜昌 443099
  • 折叠

摘要

目的 探讨常规治疗联合曲美他嗪治疗对心肌缺血再灌注损伤后心肌过氧化反应损伤、炎症因子及心功能的影响.方法 选取2023年9—12月宜昌市中心人民医院收治的100例心肌缺血再灌注损伤患者.以随机数字表法分组,各50例.对照组接受常规治疗,观察组联合曲美他嗪治疗.比较2组治疗前后患者的心肌过氧化反应损伤指标、炎症因子、心功能变化及不良反应发生情况.结果 治疗后,观察组抗凋亡蛋白B细胞淋巴瘤因子-2(B-cell lymphoma-2,Bcl-2)为(105.20±15.28)ng/mL,高于对照组的(86.20±12.65)ng/mL(P<0.05).观察组血清肌钙蛋白I(troponin I,cTn-I)、肌酸磷酸激酶同工酶(creatine kinase-MB,CK-MB)与肌酸磷酸激酶(creatine phosphokinase,CPK)水平分别为(22.68±2.84)μg/L、(148.50±35.26)U/L、(136.20±18.50)nmol/L,低于对照组的(40.26±4.32)μg/L、(196.26±53.68)U/L、(233.26±29.18)nmol/L(P<0.05).治疗后,观察组白介素6(interleukin-6,IL-6)、白介素8(interleukin-8,IL-8)与肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)水平低于对照组(P<0.05).观察组治疗后左心室舒张末内径(left ventricular end diastolic dimension,LVEDD)低于对照组,二尖瓣舒张早期最大流速(maximum early diastolic velocity of mitral valve,EV)与左心室射血分数(left ventricular ejection fraction,LVEF)高于对照组(P<0.05).2组不良反应总发生率比较,差异无统计学意义(P>0.05).结论 常规治疗联合曲美他嗪治疗可减轻心肌缺血再灌注损伤患者的心肌过氧化反应损伤与炎症反应,促使患者的心功能得到更为有效地改善.

Abstract

Objective To explore the effects of conventional therapy combined with trimetazidine treatment on myocardial peroxidation injury,inflammatory factors,and cardiac function in myocardial ischemia-reperfusion injury. Methods A total of 100 patients with myocardial ischemia-reperfusion injury at Yichang Central People's Hospital from September to December 2023 were selected and randomly divided into groups using a random number table method,with 50 patients in each group. The control group received routine treatment,while the observation group received combined treatment with trimetazidine. The myocardial peroxidation damage indexes,inflammatory factors,cardiac function changes and adverse reactions were compared before and after treatment in the two groups. Results After treatment,the B-cell lymphoma-2 (Bcl-2) in the observation group was (105.20±15.28) ng/mL,which was higher than (86.20±12.65) ng/mL in the control group (P<0.05). The serum levels of troponin I (cTn-I),creatine kinase-MB (CK-MB),and creatine phosphokinase (CPK) in the observation group were (22.68±2.84) μg/L,(148.50±35.26) U/L,(136.20±18.50) nmol/L,which were lower than (40.26±4.32) μg/L,(196.26±53.68) U/L,(233.26±29.18) nmol/L in the control group (P<0.05). After treatment,the levels of interleukin-6 (IL-6),interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the observation group were lower than those in the control group (P<0.05). After treatment,the left ventricular end diastolic dimension (LVEDD) of the observation group was lower than that of the control group,while the maximum early diastolic velocity of mitral valve (EV) and left ventricular ejection fraction (LVEF) were higher than those of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Conventional therapy combined with trimetazidine can alleviate myocardial peroxidation injury and inflammatory response in patients with myocardial ischemia-reperfusion injury,and promote more effective improvement of cardiac function.

关键词

心肌缺血再灌注损伤/曲美他嗪/心肌过氧化反应/炎症因子/心功能/不良反应

Key words

myocardial ischemia-reperfusion injury/trimetazidine/myocardial peroxidation reaction/inflammatory factors/cardiac function/adverse reactions

引用本文复制引用

出版年

2024
中国卫生标准管理
《中国卫生标准管理》杂志社

中国卫生标准管理

影响因子:1.374
ISSN:1674-9316
段落导航相关论文